content.govdelivery.com Open in urlscan Pro
2a02:26f0:6c00:2a4::1884  Public Scan

Form analysis
1 forms found in the DOM

GET https://public.govdelivery.com/accounts/USOARHIVINFO/subscriber/qualify

<form role="form" method="get" action="https://public.govdelivery.com/accounts/USOARHIVINFO/subscriber/qualify" id="sub_form">
  <div><label for="email">Email Address</label><input type="text" aria-describedby="email-input-content-description" class="sr-field stacked-text-field" id="email" name="email"><small id="email-input-content-description">e.g. name@example.com</small>
  </div>
  <div id="subscribe-button-wrapper"><input type="submit" class="sr-button reverse small stacked-submit-button" value="Subscribe"></div>
</form>

Text Content

We only use cookies that are necessary for this site to function to provide you
with the best experience. The controller of this site may choose to place
supplementary cookies to support additional functionality such as support
analytics, and has an obligation to disclose these cookies. Learn more in our
Cookie Statement.


CORRECTED ANNOUNCEMENT: UPDATES TO THE GUIDELINES FOR THE USE OF ANTIRETROVIRAL
AGENTS IN ADULTS AND ADOLESCENTS WITH HIV

HIVinfo sent this bulletin at 01/24/2022 03:47 PM EST


View as a webpage  /  Share



January 24, 2022


UPDATES TO THE GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN ADULTS AND
ADOLESCENTS WITH HIV

This notice updates and corrects an announcement on this subject sent January
20, 2022.

The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel)
updated the following sections of the Guidelines for the Use of Antiretroviral
Agents in Adults and Adolescents Living with HIV. Highlights are summarized
below:

Early (Acute and Recent) HIV Infection 

 * In the previous version of the guidelines, the Panel on Antiretroviral
   Guidelines for Adults and Adolescents (the Panel) suggested that an HIV RNA
   level of <10,000 copies/mL in a person suspected to have acute HIV may
   represent a false-positive test result. The section was updated to revise
   this threshold. The Panel noted that given the improved sensitivity and
   specificity of current HIV RNA tests in the presence of compatible symptoms
   or exposure history, even a low HIV RNA concentration (e.g., <3,000
   copies/mL) in the setting of a negative or indeterminate HIV antibody test
   result may represent acute HIV. The Panel noted that, in rare cases, an HIV
   RNA <3,000 copies/mL may represent a false-positive quantitative test result.
   In that case, repeat testing should be done to confirm the diagnosis.  
 * In this revision, the Panel also provided updated information regarding
   diagnosis of acute HIV in individuals who are receiving pre-exposure
   prophylaxis and subsequent initiation of antiretroviral therapy (ART). 

Discontinuation or Interruption of Antiretroviral Therapy 

 * This section has been updated to include discussions regarding
   discontinuation or interruption of long-acting antiretroviral drugs,
   including ibalizumab and the intramuscular formulations of cabotegravir
   and rilpivirine. The section also includes discussions regarding steps to
   take before and during ART interruption for people with HIV who participate
   in clinical trials that involve analytical treatment interruptions. 

For a complete list of updates, please see What's New in the Guidelines. To view
or download the guidelines, please see the Adult and Adolescent ARV Guidelines
section of Clinical Info’s website. The guidelines tables and recommendations
can also be downloaded as separate PDF files.

Clinical Info Welcomes Your Feedback on the latest revisions to the Guidelines
for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV.
Please send your comments with the subject line “Adult and Adolescent ARV
Guidelines” to ContactUs@hivinfo.nih.gov by February 10, 2022.



Stay Connected with HIVinfo:

     

SUBSCRIBER SERVICES:
Manage Subscriptions  |  Unsubscribe All  |  Help

 

--------------------------------------------------------------------------------

You are subscribed as Email Address.  Update your subscriptions, modify your
password or email address, or stop subscriptions at any time on your Subscriber
Preferences Page. You will need to use your email address to log in. If you have
questions or problems with the subscription service, please visit the
GovDelivery Subscriber Help Center at
https://insights.govdelivery.com/Communications/Subscriber_Help_Center.

This service is provided in collaboration with NIH’s Office of AIDS Research and
HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.


SUBSCRIBE TO UPDATES FROM HIVINFO

Email Addresse.g. name@example.com



SHARE BULLETIN



Powered by


Privacy Policy | Cookie Statement | Help